Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KuicK Research | PRODUCT CODE: 1596957

Cover Image

PUBLISHER: KuicK Research | PRODUCT CODE: 1596957

Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030

PUBLISHED:
PAGES: 600 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3300
PDF (Multi-User License)
USD 6000

Add to Cart

Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:

  • Global Peptide Cancer Drug Market Insight By Region & Indication
  • Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
  • Approved Peptide Cancer Drugs: > 30 Drugs
  • Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
  • Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
  • Insight On Peptide Cancer Drugs In Clinical Trials: > 230 Drugs
  • Insight On Commercially Approved Peptide Cancer By Brand Name, Company and Indication

In recent years, peptides have emerged as significant assets in the fight against cancer, providing new possibilities in both therapeutic and diagnostic contexts. These short sequences of amino acids, consisting of 2 to 50 residues, have attracted considerable interest from researchers and healthcare professionals due to their high specificity, reduced toxicity relative to traditional chemotherapy, and adaptable characteristics. The approval of more than 30 peptide based medications for cancer treatment by regulatory bodies globally represents a noteworthy advancement in this area.

The effectiveness of peptides in cancer therapy can be linked to their distinctive attributes. Their compact structure promotes deeper tissue infiltration, while their strong selectivity enables precise delivery of therapeutic agents to cancerous cells, sparing healthy tissue. For example, goserelin, a peptide medication sanctioned for the treatment of breast and prostate cancer, operates by accurately targeting hormone receptors, effectively inhibiting tumor growth with minimal adverse effects. Likewise, octreotide, another approved peptide medication, has demonstrated significant efficacy in managing neuroendocrine tumors by selectively binding to somatostatin receptors that are overexpressed on cancer cells.

In the field of diagnostics, peptides have transformed cancer imaging and detection. Radiolabeled peptides, such as gallium-68 DOTATATE, have become essential tools in the identification and staging of neuroendocrine tumors through PET imaging. These peptide-based diagnostic methods provide greater sensitivity and specificity compared to traditional imaging techniques, facilitating earlier detection and more precise monitoring of disease progression.

The adaptability of peptides has facilitated their incorporation into a range of therapeutic approaches. Certain peptides specifically target cancer cells by interfering with critical cellular functions, while others serve as vehicles for delivering cytotoxic agents or radioactive materials. An illustrative example is the peptide drug conjugate Lutathera, which merges a somatostatin analog with a radioactive isotope to provide targeted radiation therapy to neuroendocrine tumor cells. Furthermore, peptide vaccines have demonstrated potential in activating the immune system to identify and combat cancer cells, marking a significant advancement in cancer immunotherapy.

Continuous progress in peptide engineering and delivery mechanisms is broadening the scope of these molecules. Researchers are innovating new methods to enhance peptide stability and bioavailability, including cyclization techniques and the use of non-standard amino acids. The advent of cell-penetrating peptides has created new avenues for the direct delivery of therapeutic agents into cancer cells. For example, RGD peptides have shown potential in targeting tumor blood vessels and enhancing drug delivery to solid tumors.

The outlook for peptide-based cancer therapies is particularly encouraging. Current investigations are centered on the creation of multifunctional peptides capable of diagnosing, targeting, and treating cancer cells simultaneously, a strategy referred to as theranostics. Additionally, scientists are examining the role of artificial intelligence and machine learning in the design of more effective peptide sequences. The integration of peptides with other therapeutic modalities, such as antibodies and small molecule drugs, is anticipated to lead to more effective treatment regimens.

Recent clinical trials have highlighted the promise of innovative peptide-based strategies. For instance, research on peptide-drug conjugates that target specific cancer biomarkers has yielded positive outcomes in the treatment of resistant variants of breast and lung cancer. Furthermore, the development of peptide-based imaging agents is underway to assist in surgical interventions and to provide real-time monitoring of treatment efficacy.

Looking forward, the domain of peptide-based cancer therapeutics is advancing at a remarkable pace. The creation of more advanced delivery mechanisms, enhanced manufacturing techniques, and a deeper comprehension of cancer biology are expected to result in even more potent peptide-based therapies. The incorporation of peptides into personalized medicine, where treatments are customized to the unique cancer profiles of individual patients, signifies a promising new direction in oncology. With ongoing research and technological progress, peptides are set to assume an increasingly vital role in the future of cancer treatment and diagnosis, offering the potential for more effective, less harmful, and more individualized cancer care.

Table of Contents

1. Introduction to Peptide Therapeutics

  • 1.1 Overview of Peptide Therapeutics
  • 1.2 Classification Of Anticancer Peptides
  • 1.3 Designing & Functioning of Peptide Drugs
  • 1.4 Significance of Peptides as Cancer Therapeutics
  • 1.5 Role of Peptides in Cancer Immunotherapy

2. Global Cancer Peptide Therapeutics Market Insight

  • 2.1 Current Market Scenario
  • 2.2 Future Market Opportunities

3. Cancer Peptide Research & Market Trends by Country

  • 3.1 US
  • 3.2 China
  • 3.3 Japan
  • 3.4 South Korea
  • 3.5 Australia
  • 3.6 India
  • 3.7 Canada
  • 3.8 EU
  • 3.9 Latin America
  • 3.10 Middle East
  • 3.11 UK

4. Cancer Peptide Research & Market Trends by Indication

  • 4.1 Breast Cancer
  • 4.2 Hematological Malignancies
  • 4.3 Urothelial Cancer
  • 4.4 Prostate Cancer
  • 4.5 Lung Cancer
  • 4.6 Gastrointestinal Cancer
  • 4.7 Gynecological Cancer
  • 4.8 Skin Cancer
  • 4.9 Pancreatic Cancer
  • 4.10 CNS Cancers

5. Marketed Cancer Peptides Drugs & Generics Insight - Availability, Cost, Dosage, Indication & Patent Insight

  • 5.1 Firmagon (Degarelix)
  • 5.1 Eligard (Leuprolide)
  • 5.2 Lupron (Leuprolide Acetate)
  • 5.3 Gonax (Degarelix Acetate)
  • 5.4 Trelstar (Triptorelin)
  • 5.5 Decapeptyl/Decapeptyl DR (Treptorelin Acetate or Pamoate)
  • 5.6 Velcade (Bortizomib)
  • 5.7 Ninlaro (Ixazomib)
  • 5.8 Kyprolis (Carfilzomib)
  • 5.9 Istodax (Romidepsin)
  • 5.10 Zoladex (Goserelin)
  • 5.11 Cosmegen (Dactinomycin)
  • 5.12 Somatuline Depot (Lanreotide)
  • 5.13 Sandostatin (Octreotide Acetate)
  • 5.14 Bynfezia Pen (Octreotide)
  • 5.15 Lutathera (Lutetium Lu 177 dotatate)
  • 5.16 Mepact (Mifamurtide)
  • 5.17 Netspot (Gallium Ga 68 dotatate)
  • 5.18 Camcevi (Leuprolide)

6. Marketed Cancer Peptides Drugs Sales Insight

  • 6.1 Kyprolis
  • 6.2 Zoladex
  • 6.3 Lutathera
  • 6.4 Sandostatin
  • 6.5 Somatuline
  • 6.6 Decapeptyl SR
  • 6.7 Velcade
  • 6.8 Ninlaro
  • 6.9 Lupron

7. Global Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication & Phase

  • 7.1 Research
  • 7.2 Preclinical
  • 7.3 Phase I
  • 7.4 Phase I/II
  • 7.5 Phase II
  • 7.6 Phase II/III
  • 7.7 Phase III
  • 7.8 Preregistration
  • 7.9 Registered

8. Marketed Peptide Cancer Drugs Clinical Insight By Company, Country and Indication

9. Global Peptide Cancer Drug Market Dynamics

  • 9.1 Favorable Market Parameters
  • 9.2 Commercialization Challenges

10. Therapeutic Peptide Targets

  • 10.1 Signal Transduction Pathways
  • 10.2 Cell Cycle Regulation
  • 10.3 Cell Death Pathways
  • 10.4 Tumor Suppressor Protein
  • 10.5 Transcription Factors

11. Peptide Drugs v/s Conventional Cancer Therapeutics

  • 11.1 Peptide v/s Chemotherapy
  • 11.2 Peptide v/s Monoclonal Antibody
  • 11.3 Peptide v/s Gene Therapy
  • 11.4 Peptide v/s Immunotherapy

12. Different Approaches of Peptides in Cancer Therapeutics

  • 12.1 Hormonal Peptides
  • 12.2 Radionuclide Drug Carrier
  • 12.3 Peptide Vaccines
  • 12.4 Cytotoxic Drug Carrier
  • 12.5 Anticancer Peptides
  • 12.6 Other Anticancer Drugs Closely Related to Peptides

13. Neoantigen Vaccine: An Emerging Tumor Immunotherapy

  • 13.1 Personalized Neoantigen Based Vaccine in Cancer
  • 13.2 Clinical Progress & Future Prospects

14. Venom Peptides: New Era for Cancer Peptide Therapy

  • 14.1 Relevance of Venom Based Peptide Therapeutics
  • 14.2 Drug Development Trends & Future Growth Avenues of Venom Peptides

15. Competitive Landscape

  • 15.1 3B Pharmaceuticals
  • 15.2 AsclepiX Therapeutics
  • 15.3 Bicycle Therapeutics
  • 15.4 Biohaven Labs
  • 15.5 BrightPath Biotherapeutics
  • 15.6 Bristol-Myers Squibb
  • 15.7 Edinburgh Molecular Imaging
  • 15.8 Gnubiotics Sciences
  • 15.9 IDP Pharma
  • 15.10 Janux Therapeutics
  • 15.11 Medikine
  • 15.12 Modulation Therapeutics
  • 15.13 Novartis
  • 15.14 Parabilis Medicines
  • 15.15 PeptiDream
  • 15.16 Perspective Therapeutics
  • 15.17 Pharm-Sintez
  • 15.18 Roche
  • 15.19 Sapience Therapeutics
  • 15.20 Vigeo Therapeutics

List of Tables

  • Table 1-1: Source or Chemical Nature of Early Peptides
  • Table 5-1: Trelstar - Recommended Dose (mg/week)
  • Table 5-2: Velcade - Dosage Regimen for Patients with Previously Untreated Multiple Myeloma
  • Table 13-1: Neoantigen Vaccines in Clinical Trials
  • Table 14-1: Other Venom Peptides in Cancer Therapy

List of Figures

  • Figure 1-1: Anticancer Peptides - Classification
  • Figure 1-2: Traditional Structure-Based Design Strategies Used in Peptide Drug Discovery
  • Figure 1-3: Peptides - Significance as Cancer Therapeutics
  • Figure 1-4: US - Per Unit Cost of Cancer Drugs (US$)
  • Figure 1-5: Peptides - Role in Cancer Immunotherapy
  • Figure 2-1: Global - Peptide Therapeutic Market Size (US$ Billion), 2023 - 2030
  • Figure 2-2: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2023 - 2030
  • Figure 3-1: 177Lu-EB-FAPI PRRT Phase 1 (NCT06081322) Study - Initiation & Completion Year
  • Figure 3-2: PeptiDream - Peptide Discovery Platform System (PDPS) Features
  • Figure 4-1: PVX-410 Phase 2 (NCT04634747) Study - Initiation & Completion Year
  • Figure 4-2: TH1902 Phase 1 (NCT04706962) Study - Initiation & Completion Year
  • Figure 4-3: Multi Peptide Vaccine Phase 1 (NCT06252584) Study - Initiation & Completion Year
  • Figure 4-4: SVN53-67/M57-KLH Phase 1 (NCT02334865) Study - Initiation & Completion Year
  • Figure 4-5: Zelenectide Pevedotin Phase 1 (NCT04561362) Study - Initiation & Completion Year
  • Figure 4-6: Zelenectide Pevedotin Phase 2/3 (NCT06225596) Study - Initiation & Completion Year
  • Figure 4-7: Alphalex Exatecan Phase 1/2 (NCT04902872) Study - Initiation & Completion Year
  • Figure 4-8: Personalized Cancer Vaccine Phase 1/2 (NCT06529822) Study - Initiation & Completion Year
  • Figure 4-9: PGV001 Based Personalized Multipeptide Vaccine Phase 1 (NCT05010200) Study - Initiation & Completion Year
  • Figure 4-10: TB511 Phase 1/2 (NCT06400160) Study - Initiation & Completion Year
  • Figure 4-11: MUC1 Peptide Poly-ICLC Vaccine Phase 1 (NCT03300817) Study - Initiation & Completion Year
  • Figure 4-12: UCPVax Phase 1/2 (NCT02818426) Study - Initiation & Completion Year
  • Figure 4-13: TH1902 Phase 1/2 (NCT04706962) Study - Initiation & Completion Year
  • Figure 4-14: ELI-002 7P Phase 1/2 (NCT05726864) Study - Initiation & Completion Year
  • Figure 4-15: Linaclotide Phase 2 (NCT03796884) Study - Initiation & Completion Year
  • Figure 4-16: CBX-12-201 Phase 2 (NCT06315491) Study - Initiation & Completion Year
  • Figure 4-17: UCPVax Phase 2 (NCT03946358) Study - Initiation & Completion Year
  • Figure 4-18: IO102-IO103 Phase 3 (NCT05155254) Study - Initiation & Completion Year
  • Figure 4-19: Dendritic Cell Vaccine Phase 1 (NCT03092453) Study - Initiation & Completion Year
  • Figure 4-20: LTX-315 - Mechanism of Action
  • Figure 4-21: LTX-315 Phase 2 (NCT06651151) Study - Initiation & Completion Year
  • Figure 4-22: LTX-315 Phase 2 (NCT04796194) Study - Initiation & Completion Year
  • Figure 4-23: Peptide Vaccine Phase 1 (NCT06564623) Study - Initiation & Completion Year
  • Figure 4-24: Motixafortide Phase 2 (NCT04543071) Study - Initiation & Completion Year
  • Figure 4-25: Personalized Neoantigen Vaccine Phase 1 (NCT03558945) Study - Initiation & Completion Year
  • Figure 4-26: SurVaxM Phase 2 (NCT05163080) Study - Initiation & Completion Year
  • Figure 4-27: SurVaxM Phase 2 (NCT02455557) Study - Initiation & Completion Year
  • Figure 4-28: SurVaxM Phase 1 (NCT04978727) Study - Initiation & Completion Year
  • Figure 4-29: ST101 Phase 2 (NCT04478279) Study - Initiation & Completion Year
  • Figure 4-30: Peptide VaCcine Phase 1 (NCT04808245) Study - Initiation & Completion Year
  • Figure 5-1: Firmagon - Patent Issue & Expiration Years
  • Figure 5-2: Firmagon - Price per Unit of 80 mg & 120 mg Powder for Subcutaneous Injection (US$), November'2024
  • Figure 5-3: Firmagon - Starting & Maintenance Dosage (mg)
  • Figure 5-4: Firmagon - Treatment Costs of Initial Cycle and Maintenance Cycle (US$), May'2023
  • Figure 5-5: Eligard - Cost of Different doses of Extended-Release Subcutaneous Powder for Injection (US$), November'2024
  • Figure 5-6: Eligard - Recommended Dosage for Prostate Cancer on Monthly Basis (mg)
  • Figure 5-7: Eligard - Annual Treatment cost of Prostate Cancer using Different available Doses (US$), May'2023
  • Figure 5-8: Lupron - Patent Issue & Expiration Year for Sustained Release Preparation
  • Figure 5-9: Lupron - Price of Lupron Depot Intramuscular Kits by Dose (US$), November'2024
  • Figure 5-10: Lupron - Price of Lupron Depot Intramuscular Powder by Dose (US$), November'2024
  • Figure 5-11: Lupron - Average Annual Treatment Costs by Depot Type, November'2024
  • Figure 5-12: Gonax - Cost of Supply of Powder for Subcutaneous Injection (US$), November'2024
  • Figure 5-13: Gonax - Starting & Maintenance Dosage (mg)
  • Figure 5-14: Trelstar - Patent Issue & Expiration Year
  • Figure 5-15: Trelstar - Cost per Unit & Supply of Powder for Intramuscular Injection (US$), November'2024
  • Figure 5-16: Trelstar - Annual Treatment Cost by Dose (US$), November'2024
  • Figure 5-17: Decapeptyl SR - Price for a Supply of 3mg, 11.25mg & 22.5mg Powder for Injection (GBP/US$), November'2024
  • Figure 5-18: Decapeptyl SR - Recommended Dosage for Prostate Cancer (mg/week)
  • Figure 5-19: Decapeptyl SR - Annual Prostate Cancer Treatment Cost by Dose (US$), November'2024
  • Figure 5-20: Velcade - Price for a Supply of 3.5 mg Powder for Injection (US$), November'2024
  • Figure 5-21: Bortizomib - Price for Supply of Injectable Powder For Injection by Dose (US$), November'2024
  • Figure 5-22: Ninlaro - Patent Issue & Expiration Year
  • Figure 5-23: US - Price per Unit & Supply of Ninlaro Capsule (US$), November'2024
  • Figure 5-24: EU - Price of Supply of Ninlaro Capsule (EUR/US$), November'2024
  • Figure 5-25: Ninlaro - Recommended Dose & Dose Reductions for Treatment of Multiple Myeloma (mg/week)
  • Figure 5-26: Kyprolis - Issue & Expiration Year of Patents Assigned to Proteolix Inc
  • Figure 5-27: Kyprolis - Issue & Expiration Year of Patent Assigned to Cydex Pharmaceutical
  • Figure 5-28: Kyprolis - Issue & Expiration Year of Patents Assigned to Onyx Therapeutics
  • Figure 5-29: Kyprolis - Price of 10mg, 30mg & 60mg Intravenous Powder for Injection (US$), November'2024
  • Figure 5-30: Kyprolis - Initial Dose & Maintenance Dose for Treatment of Multiple Myeloma (mg/m2/week)
  • Figure 5-31: Kyprolis - Initial Dose & Maintenance Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Twice a Week)
  • Figure 5-32: Romidepsin - FDA Approval Year by Indication
  • Figure 5-33: Istodax - Price for a Supply of Intravenous Powder (US$), November'2024
  • Figure 5-34: Romidepsin - Price per Unit & Supply by Dose Form (US$), November'2024
  • Figure 5-35: Zoladex - Cost of 3.6 mg & 10.8 mg Implant (US$), November'2024
  • Figure 5-36: Zoladex - Recommended Dose for Prostate cancer Management on Monthly Basis (mg/week)
  • Figure 5-37: Zoladex - Annual Treatment Cost using 3.6mg & 10.8mg Implant (US$), November'2024
  • Figure 5-38: Dactinomycin - Price for Generic & Branded 0.5 mg Powder for Injection (US$), November'2024
  • Figure 5-39: Somatuline Depot - Price per Unit & supply of Subcutaneous Solution by Dose (US$), November'2024
  • Figure 5-40: Lanreotide - Price per Unit & Supply of Subcutaneous Solution (US$), November'2024
  • Figure 5-41: Somatuline Depot - Treatment cost of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), November'2024
  • Figure 5-42: Sandostatin - Price per Unit & 10-Vial Supply by Dose (US$), November'2024
  • Figure 5-43: Sandostatin LAR - Price of Intramuscular Powder for Injection by Dose (US$), November'2024
  • Figure 5-44: Octreotide - Price per Unit & Supply of 10 mL Injectable Solution (US$), November'2024
  • Figure 5-45: Octreotide - Price per Unit & Supply of 5 mL Injectable Solution (US$), November'2024
  • Figure 5-46: Octreotide - Price per Unit & Supply of Intramuscular Powder for Injection by Dose (US$), November'2024
  • Figure 5-47: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg/day)
  • Figure 5-48: Bynfezia Pen - Patent Issue & Expiration Year
  • Figure 5-49: Bynfezia Pen - Price per Unit & Supply of Subcutaneous Solution (US$), November'2024
  • Figure 5-50: Bynfezia Pen - Mean Dose for First 2 Week & Subsequent Weeks (mcg/day)
  • Figure 5-51: Lutathera - Patent Issue & Expiration Years
  • Figure 5-52: Lutathera - RDP & ODE Regional Expiry Years
  • Figure 5-53: Mepact - Recommended Number of Dose Administration/ Week for 12 & 24 Weeks Treatment
  • Figure 6-1: Kyprolis - Global Sales (US$ Million), 2020-2024
  • Figure 6-2: Kyprolis - Global Quarterly Sales Values (US$ Million), Q1-Q3'2024
  • Figure 6-3: Kyprolis - US Annual Sales (US$ Million), 2020-2024
  • Figure 6-4: Kyprolis - US Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-5: Kyprolis - ROW Annual Sales (US$ Million), 2020-2024
  • Figure 6-6: Kyprolis - ROW Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-7: Zoladex - Global Sales (US$ Million), 2020-2024
  • Figure 6-8: Zoladex - Global Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-9: Zoladex - Global Sales By Region (US$ Million), 2024
  • Figure 6-10: Zoladex - Global Sales By Region (%), 2024
  • Figure 6-11: Zoladex - Global Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-12: Zoladex - US Annual Sales (US$ Million), 2020-2024
  • Figure 6-13: Zoladex - US Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-14: Zoladex - Europe Annual Sales (US$ Million), 2020-2024
  • Figure 6-15: Zoladex - Europe Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-16: Zoladex - EM Annual Sales (US$ Million), 2020-2024
  • Figure 6-17: Zoladex - EM Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-18: Zoladex - ROW Annual Sales (US$ Million), 2020-2024
  • Figure 6-19: Zoladex - ROW Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-20: Lutathera - Global Sales (US$ Million), 2020-2024
  • Figure 6-21: Lutathera - Global Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-22: Lutathera - Global Sales By Region (US$ Million), 2024
  • Figure 6-23: Lutathera - US Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-24: Lutathera - ROW Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-25: Sandostatin - Global Sales (US$ Million), 2020-2024
  • Figure 6-26: Sandostatin - Global Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-27: Sandostatin - US Annual Sales (US$ Million), 2020-2024
  • Figure 6-28: Sandostatin - US Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-29: Sandostatin - ROW Annual Sales (US$ Million), 2020-2024
  • Figure 6-30: Sandostatin - ROW Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-31: Somatuline - Global Sales (US$ Million), 2020-2024
  • Figure 6-32: Somatuline - Global Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-33: Somatuline - NA Sales (US$ Million), 2022-2024
  • Figure 6-34: Somatuline - NA Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-35: Somatuline - Europe Sales (US$ Million), 2022-2024
  • Figure 6-36: Somatuline - Europe Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-37: Somatuline - ROW Sales (US$ Million), 2022-2024
  • Figure 6-38: Somatuline - ROW Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-39: Decapeptyl - Global Sales (US$ Million), 2020-2024
  • Figure 6-40: Decapeptyl - Global Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-41: Decapeptyl - Europe Sales (US$ Million), 2022-2024
  • Figure 6-42: Decapeptyl - Europe Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-43: Decapeptyl - ROW Sales (US$ Million), 2022-2024
  • Figure 6-44: Decapeptyl - ROW Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-45: Velcade - Global Sales (US$ Million), 2020-2024
  • Figure 6-46: Velcade - Global Quarterly Sales (US$ Million), Q1-Q4'2023
  • Figure 6-47: Ninlaro - Global Sales (US$ Million), 2020-2024
  • Figure 6-48: Ninlaro - Global Quarterly Sales (US$ Million), Q1-Q3'2024
  • Figure 6-49: Global - Lupron Annual Sales (US$ Million), 2019-2021
  • Figure 6-50: US - Lupron Annual Sales (US$ Million), 2019-2021
  • Figure 6-51: ROW - Lupron Annual Sales (US$ Million), 2019-2021
  • Figure 7-1: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2024 Till 2030
  • Figure 9-1: Global Peptide Cancer Drug Market - Favorable Parameters
  • Figure 9-2: Global Peptide Cancer Drug Market - Commercialization Challenges
  • Figure 10-1: Therapeutic Peptides Based on Their Biological Targets
  • Figure 10-2: MAPK Signaling Pathways
  • Figure 10-3: Cell Cycle in Eukaryotes
  • Figure 10-4: Cell Death Pathways
  • Figure 10-5: Features of Bcl-2 Family Proteins
  • Figure 11-1: Monoclonal Antibody - Limitations
  • Figure 11-2: Monoclonal Antibodies & Peptide Therapeutics - Cost of Production per gram (US$)
  • Figure 11-3: Pre-Requisite for Gene Therapy
  • Figure 11-4: Gene Therapy - Limitations
  • Figure 11-5: Immunotherapy - Drawbacks
  • Figure 12-1: Different Approaches of Peptide in Cancer Management
  • Figure 12-2: LHRH Agonist & LHRH Antagonist - Mode of Action
  • Figure 12-3: Somatostatin Analogs - Effects
  • Figure 12-4: Peptide Receptor Radionuclide Therapy
  • Figure 12-5: Peptide Vaccines - Mechanism
  • Figure 13-1: Neoantigen Vaccines - Benefits
  • Figure 13-2: Neoantigen Vaccine Production
  • Figure 13-3: Neoantigen Vaccine - Mode of Action
  • Figure 14-1: Venom Peptides - Advantages
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!